Oral Biolife (OBL), a pioneering biotechnology company, has announced significant progress in the development of its flagship product, Ambrilux Dental Gel, designed to treat both human and companion animal periodontal disease. Recent studies have demonstrated the gel’s effectiveness in promoting bone regeneration in dogs with periodontal disease, marking a key breakthrough in non-invasive dental care.
In the proof-of-concept study, Ambrilux Dental Gel was applied to three beagles induced with periodontal disease. Radiographs taken 28 and 29 days after the first and second applications, respectively, revealed increased bone regeneration in all treated dogs. In contrast, only one of three control animals showed detectable bone growth. Importantly, no adverse events or safety concerns were reported during the study, adding to the gel’s promise as a safe and effective treatment option.
“This is a major milestone in our journey. The success of this study reinforces our confidence that Ambrilux Dental Gel has the potential to revolutionize dental care by offering a less invasive, more accessible option for patients,” said Bill Breitenbach, CEO of Oral Biolife, in a news release.
Oral Biolife’s innovation is particularly timely as periodontal disease affects a staggering 80-90% of dogs over the age of two, with smaller breeds facing an even higher risk. Symptoms include mouth pain, drooling, appetite changes, and behavioral shifts. Proper home care and regular veterinary dental cleanings are essential to prevent the onset of this disease.
In July 2024, OBL formed a strategic partnership with a leading global animal health company to further develop its periodontal disease treatment for companion animals. This partnership marks a crucial step toward making Ambrilux Dental Gel accessible to veterinarians and raising awareness of animal oral health.
“At Oral Biolife, our mission has always been to find ways to provide non-invasive dental care. We are encouraged by these results and eager to continue our research to further validate the safety and efficacy of Ambrilux Dental Gel,” said Stella Vnook, president of Oral Biolife.
As OBL continues its research and development, Ambrilux Dental Gel could be a transformative solution for both human and veterinary dental care, offering a promising alternative to traditional, invasive treatments.
Related topics:
